- Home
- JACS vs SGMT Comparison
JACS vs SGMT Comparison
Compare JACS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JACS
- SGMT
- Stock Information
- Founded
- JACS 2024
- SGMT 2006
- Country
- JACS United States
- SGMT United States
- Employees
- JACS N/A
- SGMT N/A
- Industry
- JACS
- SGMT
- Sector
- JACS
- SGMT
- Exchange
- JACS NYSE
- SGMT Nasdaq
- Market Cap
- JACS 303.6M
- SGMT 269.2M
- IPO Year
- JACS 2024
- SGMT 2023
- Fundamental
- Price
- JACS $10.33
- SGMT $9.64
- Analyst Decision
- JACS
- SGMT Strong Buy
- Analyst Count
- JACS 0
- SGMT 5
- Target Price
- JACS N/A
- SGMT $26.60
- AVG Volume (30 Days)
- JACS 73.5K
- SGMT 2.0M
- Earning Date
- JACS 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- JACS N/A
- SGMT N/A
- EPS Growth
- JACS N/A
- SGMT N/A
- EPS
- JACS N/A
- SGMT N/A
- Revenue
- JACS N/A
- SGMT N/A
- Revenue This Year
- JACS N/A
- SGMT N/A
- Revenue Next Year
- JACS N/A
- SGMT N/A
- P/E Ratio
- JACS $267.37
- SGMT N/A
- Revenue Growth
- JACS N/A
- SGMT N/A
- 52 Week Low
- JACS $9.94
- SGMT $1.73
- 52 Week High
- JACS $10.41
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- JACS N/A
- SGMT 68.58
- Support Level
- JACS N/A
- SGMT $7.80
- Resistance Level
- JACS N/A
- SGMT $9.89
- Average True Range (ATR)
- JACS 0.00
- SGMT 0.95
- MACD
- JACS 0.00
- SGMT -0.01
- Stochastic Oscillator
- JACS 0.00
- SGMT 76.43
About JACS JACKSON ACQUISITION COMPANY II
Jackson Acquisition Co II is a newly incorporated blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.